Media Coverage

11/18/19
News outlets reported on a retrospective five-year study of 1,314 patients with multiple sclerosis (MS) by researchers in the Jacobs School of Medicine and Biomedical Sciences. The team found that atrophied brain lesion volume is the only marker from MRI scans that can accurately predict which patients will progress to the most severe form of the disease. “This study corroborates initial reports from our group regarding using atrophied lesion volume as a potential MRI marker of disease progression in a large, population-based cohort of MS patients followed in clinical routine,” said Robert Zivadinov, MD, PhD, professor of neurology in the Jacobs School and director of the Buffalo Neuroimaging Analysis Center and the Center for Biomedical Imaging at UB’s Clinical and Translational Science Institute.
11/1/19
Research on molecular mechanisms behind heroin addiction relapse is led by David Dietz, PhD, associate professor and chair of pharmacology and toxicology, who said this study is one of few that examine the changes in the brain that cause people to relapse. “In the not too distant future, with all the findings, we can hopefully start to find real treatment to relieve the horrific conditions that people suffer from addiction with and break the cycle of drug-taking, relapse, drug-taking, relapse,” he said.
11/1/19
Susan S. Baker, MD, PhD, professor of pediatrics, is quoted in an articles on research that found strains of the bacterium Klebsiella pneumonia, which produces high levels of alcohol, in 60 percent of patients with nonalcoholic fatty liver disease, a common disorder in which fat builds up in the liver. Baker, who was not involved in the study, said, “Other bacteria have been shown to make alcohol, so that… verifies what other researchers have seen. We’ve never really been able to induce the inflammation that you see [in people], but they were able to do that.”
11/1/19
Preclinical research conducted by Tracey A. Ignatowski, PhD, assistant professor of pathology and anatomical sciences, is demonstrating that perispinal injection of an antibody that blocks tumor necrosis factor-alpha alleviates chronic neuropathic pain. 
10/7/19
The Buffalo News and the Lockport Union-Sun & Journal report on a new partnership for stroke imaging between Niagara Falls Memorial Medical Center and doctors from the Jacobs School of Medicine and Biomedical Sciences as UB Neurosurgery takes charge of the stroke care program at the hospital. “The treatment of stroke has changed in our lifetime. The key has been imaging,” said Kenneth V. Snyder, MD, PhD, associate professor of neurosurgery, who is part of the hospital’s treatment team.
10/7/19
Reports on a new scientific statement by Steven A. Lipshultz, MD, A. Conger Goodyear Professor and chair of pediatrics, and colleagues about cardiomyopathies in children provides insight into the diagnosis and treatment of the diseases as well as identifying future research priorities. “This statement is designed to give medical professionals an overview of what we currently know about cardiomyopathies in children. Although we are able to provide effective treatments in many cases, research is urgently needed to better understand the causes of the diseases so we can help children with cardiomyopathies live their best lives,” Lipshultz said.
10/7/19
Articles about a new report from the American Heart Association that aims to raise awareness about cardiomyopathy in children and urges that more research be conducted to find better treatments interviews Steven E. Lipshultz, MD, A. Conger Goodyear Professor and chair of pediatrics, who chaired the statement’s writing committee. “Everybody wants clinical practice guidelines, but this field hasn’t done enough clinical trials to be able to say, ‘There’s really strong evidence that, if you see this, you should use this medicine, or you should treat in that way,’” he said.
10/4/19
A number of news stories reported on a new digital method of classifying diabetic neuropathy developed by Pinaki Sarder, PhD, assistant professor of pathology and anatomical sciences, and Brandon Ginley, a student in the computational cell biology, anatomy and pathology doctoral program.
10/4/19
In stories about vaping-related illnesses, Sanjay Sethi, MD, professor of medicine and chair of pulmonary, critical care and sleep medicine, said these illnesses are showing up in people, for the most part, who are vaping marijuana and black market products. “It can be really challenging to support these patients and find the right, specific treatment for them,” he said.
10/2/19
Technology.org reports that UB researchers will study the nutrition practices of emergency medical service workers. The study will examine the on- and off-duty eating habits of EMS providers. The goal is to shed light on the chronic health conditions among EMS compared to the public. Brian Clemency, DO, associate professor of emergency medicine and director of the EMS fellowship in the Jacobs School of Medicine and Biomedical Sciences, and David P. Hostler III, PhD, professor and chair of exercise and nutrition sciences in the School of Public Health and Health Professions and  clinical professor of emergency medicine in the Jacobs School, are co-authors of the study. The story was also picked up by EMS1.
9/30/19
News accounts detailed the state Department of Health announcing that it will launch the Buffalo Medication Assisted Treatment and Emergency Referrals, or Buffalo MATTERS, program across New York, and interview Joshua J. Lynch, DO, clinical assistant professor of emergency medicine, who developed the program with others in the Department of Medicine. “If somebody comes in with chest pain, we would never just blow them off and send them home,” he said. “That’s what we used do that for patients with opioid-use disorder. I think we’ve wholeheartedly now realized in the medical community that this is a potentially life-threatening chronic disease.”
9/30/19
Stories about new research that found that the risks outweigh the benefits for people who are taking low-dose aspirin to prevent a heart attack or stroke interviews John M. Canty Jr., SUNY Distinguished Professor and Albert and Elizabeth Rekate Professor of medicine and chief of the Division of Cardiovascular Medicine. “No one under the age of 40 should be on aspirin unless there are very unique circumstances,” Canty said.
9/27/19
An article on the website of the National Science Foundation reports on the work of a trio of researchers in the Department of Pathology and Anatomical Sciences — professor Michal K. Stachowiak, PhD, and assistant professors Ewa K. Stachowiak, PhD, and Yongho Bae, PhD — and Josep M. Jornet, PhD, assistant professor of electrical engineering in the Department of Electrical Engineering, that showed that tiny brain implants can wirelessly control FGFR1 — a gene that plays a key role in how humans grow from embryos to adults — in lab-grown tissue. “The potential of optogenomic interfaces is enormous,” Jornet said. “It could drastically reduce the need for medicinal drugs and other therapies for certain illnesses. It could also change how humans interact with machines.”
9/23/19
A UB study with Washington University in St. Louis focuses on the construction of antibiotic scaffolds and how new understanding about their nature can help scientists search for new classes of antibiotics through DNA sequencing and genome mining. “The solution of this structure expands on previous discoveries to provide views of the molecular interactions between catalytic domains in a brand new way,” said Andrew M. Gulick, PhD, associate professor of structural biology.
9/23/19
Research led by Robert Zivadinov, MD, PhD, professor of neurology, found that while a commonly used imaging linear contrast agent, gadodiamide, does accumulate in the brain early in the disease, there is no discernible clinical impact. “This study is one of the first to investigate the longitudinal association between well-established clinical and MRI outcomes of disease severity and gadolinium deposition,” he said. “The findings from this study should be incorporated into a risk-versus-benefit analysis when determining the need for GBCA administration in individual MS patients.”